Non-Invasive Prenatal Testing Fails Due to Low Fetal Fraction
A 38-year-old woman at 12 weeks gestation undergoes non-invasive prenatal testing (NIPT) for fetal aneuploidy. The laboratory uses massively parallel sequencing of cell-free DNA (cfDNA) from maternal plasma. The result reports a fetal fraction of 3.5%, which is below the laboratory's threshold of 4% for reliable aneuploidy assessment. The laboratory reports 'no call' due to low fetal fraction. The patient is obese (BMI 35) and has a history of a prior child with trisomy 21. The clinician asks the laboratory for guidance on repeat testing. The laboratory's policy is to offer a redraw at 14-16 weeks gestation, and if the fetal fraction remains low, to consider invasive testing. The patient is anxious and wants definitive answers.
1. Why is the fetal fraction low, and what factors can affect it?
Read the worked answer
Fetal fraction is the proportion of cell-free DNA in maternal plasma that is of placental origin. A fetal fraction below 4% is associated with a higher risk of false-negative results for fetal aneuploidy. Maternal obesity is a known factor associated with lower fetal fraction, possibly due to increased maternal cfDNA from adipose tissue dilution. Other factors include early gestational age, fetal aneuploidy (some aneuploidies are associated with lower fetal fraction), and maternal conditions. In this case, the patient's BMI of 35 likely contributes to the low fetal fraction. The laboratory should explain that a redraw at a later gestational age may yield a higher fetal fraction, but there is no guarantee. If the fetal fraction remains low, the patient should be offered diagnostic testing (chorionic villus sampling or amniocentesis) for definitive diagnosis.
2. What are the quality assurance and ethical considerations for reporting a 'no call' NIPT result?
Read the worked answer
Quality assurance considerations include ensuring that the fetal fraction is accurately measured and that the laboratory's threshold for reporting is validated. The laboratory should have a clear policy for 'no call' results, including recommendations for redraw or alternative testing. The report should clearly state the reason for the 'no call' and the limitations of the test. Ethical considerations include the patient's autonomy and the need for informed consent. The patient should be counseled about the meaning of a 'no call' result and the options for further testing. The laboratory should avoid causing unnecessary anxiety and should provide clear guidance. Additionally, the laboratory should ensure that the report is compliant with regulatory requirements, such as those from CAP and CLIA, and that the patient's privacy is protected.